November 21, 2017 / 5:16 PM / in 25 days

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

Nov 21 (Reuters) - AB SCIENCE SA:

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

* ‍RESEARCH DEMONSTRATES THAT MASITINIB ENHANCES DCK-DEPENDENT ACTIVATION OF GEMCITABINE​

* ‍MASITINIB WAS FOUND TO BE MOST ACTIVE OF KINASE INHIBITORS TESTED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below